Advertisement
Advertisement
U.S. Markets open in 3 hrs 34 mins
Advertisement
Advertisement
Advertisement
Advertisement

IMV Inc. (IMV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0000+0.0780 (+8.46%)
At close: 04:00PM EDT
1.0200 +0.02 (+2.00%)
After hours: 07:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9220
Open0.9900
Bid0.0000 x 1200
Ask0.0000 x 800
Day's Range0.9500 - 1.0000
52 Week Range0.9000 - 2.5000
Volume52,899
Avg. Volume90,066
Market Cap83.886M
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-0.4790
Earnings DateMar 15, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Business Wire

    IMV Inc. Announces First Quarter 2022 Financial and Operational Results

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 13, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022.

  • Business Wire

    IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 06, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company’s 2022 first quarter financial and operational results.

  • Business Wire

    IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., April 28, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company’s lead compound, maveropepimut-S (MVP-S), will be showcased in two presentations in breast and ovarian cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held in-person and virtua

Advertisement
Advertisement